Indivior Pharmaceuticals (INDV) has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program, Indivior said Monday.
The company will make a $175 million upfront payment to Barclays and expects to receive an initial delivery of 3,717,473 shares following execution.
Indivior said it expects final settlement no later than the end of June.